Oxatect indications
Oral
Allergic conditions
Adult: As anhydrous substance: 30 mg bid.
Child: As anhydrous substance: Initially, 0.5 mg/kg bid. Optimal dose: 0.5-1 mg/kg bid.
Hepatic impairment: Initiate at 50% of the normal dose.
Oxatect description
A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.
Oxatect dosage
Oral
Allergic conditions
Adult: As anhydrous substance: 30 mg bid.
Child: As anhydrous substance: Initially, 0.5 mg/kg bid. Optimal dose: 0.5-1 mg/kg bid.
Hepatic impairment: Initiate at 50% of the normal dose.
Oxatect interactions
May enhance effects of CNS depressants e.g. alcohol, barbiturates, hypnotics, opioid analgesics, anxiolytic sedatives and tranquillizers. Anticholinergic effects of atropine, TCAs, MAOIs may be enhanced. May mask signs of ototoxicity caused by aminoglycosides.
Oxatect side effects
Sedation, inability to concentrate, lassitude, dizziness, hypotension, muscular weakness, incoordination. Nausea, vomiting, diarrhoea or constipation, epigastric pain. Headache, blurred vision, tinnitus, elation or depression, irritability, nightmares, anorexia, urinary retention, dry mouth, chest tightness, dysuria and tingling. Rash, urticaria. Agranulocytosis, haemolytic anaemia. Increased appetite, wt gain. Convulsions, increased transaminase, hepatitis. Dyskinetic neurological reactions (infants and young children).
Potentially Fatal: Anaphylactoid reactions, angioedema.
Oxatect contraindications
Oxatect should not be given to patients who are hypersensitive to erythromycin, sulfonamides, or any component of the formulation, who have hepatic dysfunction, and porphyria. It is containdicated in infants of less than 2 months of age.
Oxatect can not be used concurrently with pimozide or cisapride.
Active ingredient matches for Oxatect:
Oxatomide in Japan.
List of Oxatect substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Oxamide (Taiwan) | |
| Oxamide 30 mg x 500's | |
| Oxatokey (Spain) | |
| Oxatomide (Argentina, Greece, Indonesia, Italy, Netherlands, South Africa, South Korea, Taiwan, Thailand) | |
| Oxatomide 0.2% (Japan) | |
| Oxatomide 2% (Japan) | |
| Oxatomide 2% Iwaki (Japan) | |
| Oxatomide 2% Nichi-iko (Japan) | |
| Oxatomide 2% Taiyo (Japan) | |
| Oxatomide DS 2% (Japan) | |
| Oxatomide EMEC (Japan) | |
| Oxatomide Iwaki (Japan) | |
|
sponsored
| |
| Oxatomide Kunihiro (Japan) | |
| Oxatomide Nichi-iko (Japan) | |
| Oxatomide Sannova (Japan) | |
| Oxatomide Taiyo (Japan) | |
| Oxatomide Tanabe (Japan) | |
| Oxatomide ZE (Japan) | |
| Oxatomide Zensei (Japan) | |
| Oxatowa (Japan) | |
| Oxatowa 2% (Japan) | |
| Oxatowa DS 2% (Japan) | |
| Oxleti (Spain) | |
| Oxtin (Indonesia) | |
| Oxtin 30 mg x 5 x 10's (Guardian) | $ 13.95 |
| Pepecin (Japan) | |
| Pepecin 2% (Japan) | |
| Sekitarl (Japan) | |
| Sekitarl 0.2% (Japan) | |
| Selmalen (Japan) | |
| Spaclit (Japan) | |
| Tanzal (Spain) | |
| Taurustan (Japan) | |
| Taurustan DS 2% (Japan) | |
| Tinset (Argentina, Chile, Costa Rica, Cyprus, Dominican Republic, Egypt, El Salvador, France, Greece, Guatemala, Honduras, Indonesia, Italy, Jordan, Lebanon, Luxembourg, Mexico, Netherlands, Nicaragua, Panama, Portugal, Saudi Arabia, South Africa, Sudan, Taiwan, Thailand, United Arab Emirates, Yemen) | |
| Gel; Topical; Oxatomide Hydrate 5% (Cilag) | |
| Suspension; Oral; Oxatomide 2.5 mg / ml (Cilag) | |
| Tablet; Oral; Oxatomide 30 mg (Cilag) | |
| Tinset 30 mg x 250's (Cilag) | |
| Tinset 30 mg x 25 x 10's (Cilag) | |
| Tinset 30 mg x 50 x 10's (Cilag) | |
| Tinset 30 mg x 50's (Cilag) | $ 18.41 |
| Ulymin (Taiwan) | |
| Ulymin 30 mg x 100 x 10's | |
| Ulymin 30 mg x 1000's | |
See 65 substitutes for Oxatect | |
References
- PubChem. "oxatomide". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "Oxatomide". http://www.drugbank.ca/drugs/DB12877 (accessed September 17, 2018).
- DTP/NCI. "oxatomide: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Oxatect are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Oxatect. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
